

Decision of
amending the list of substances classified as narcotic drugs

The Director-General of the French National Agency for the Safety of Medicinal and Health Products (Agence nationale de sécurité du médicament et des produits de santé),

Having regard to the Public Health Code, in particular Articles L. 5132-1, L. 5132-7, L. 5132-8, L. 5432-1, R. 5132-27 et seq.;

Having regard to the Criminal Code, in particular Articles 222-34 to 222-43 thereof;

Having regard to the amended Order of 22 February 1990 establishing the list of substances classified as narcotic drugs;

Having considered the mechanism of action of synthetic cannabinoids, whether or not they are phytocannabinoid derivatives, responsible for their similar psychoactive effects to delta-9-tetrahydrocannabinol, the potential for abuse thereof and the potential to cause addiction, and the immediate health risks associated with their use;

Whereas, in view of their psychoactive effects similar to those of delta-9-tetrahydrocannabinol, it is necessary, as a matter of precaution in the interests of public health, to classify these substances without delay;

Hereby decides

Article 1: The list referred to in Article L. 5132-7 of the Public Health Code shall be drawn up in accordance with the annexes to the aforementioned Order of 22 February 1990, subject to the amendments introduced by this Decision.

Article 2: The following words are added to Annex IV to the Order of 22 February 1990 establishing the list of substances classified as narcotic drugs:

The following cannabinoids:

- H2-CBD or dihydrocannabidiol or H2-cannabidiol;
- H4-CBD or tetrahydrocannabidiol or H4-cannabidiol;
- Any substance derived from the benzo[c]chromene ring, whether or not partly or wholly hydrogenated on ring A (defined as the unsaturated methyl-carrying ring in position 9 of that ring in tetrahydrocannabinol), whether or not substituted in one of the following locations in the ring:
 - o In position 1 with a hydroxyl function, whether esterified or not, or an alkoxy function;
 - o In position 2 or 4 with a carboxyl function;
 - o In position 3 with an adamantyl substitute or with an alkyl, alkenyl, alkynyl, alkynyl cyanoalkyl, haloalkyl, cyanoalkynyl, haloalkynyl and alkoxy chain, whether or not that chain is itself substituted by one or more alkyl substitutes, whether or not heterocyclic, whether or not these rings or heterocycling ring structures are saturated;
 - o In position 6 by one or two alkyl groups;
 - o In position 9 by a ketone, alkyl, hydroxyalkyl or alkoxy function.

excluding cannabinol or CBN.

- 5F-CUMYL-PEGACLONE or 5F-SGT-151;
- CUMYL-CH-MEGACLONE or SGT-270;
- 7APAICA;
- 5F-7APAICA;
- CUMYL-P7AICA;
- 5F-CUMYL-P7AICA;
- BZO-HEXOXIZID or MDA-19;
- BZO-POXIZID or 5C-MDA-19.

Article 3: This Decision shall be published on the website of the French National Agency for the Safety of Medicinal and Health Products and shall enter into force 10 days after the date of its publication.

Dated